Sympathectomized tumor-bearing mice survive longer but develop bigger melanomas

Andersen BL, Farrar WB, Golden-Kreutz D, Emery CF, Glaser R, Crespin T, Carson WE, 3^rd. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 21, 953–961, 2007.10.1016/j.bbi.2007.03.005Search in Google Scholar

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29, 2635–2644, 2011.10.1200/JCO.2010.33.5422Search in Google Scholar

Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 64, 5551–5555, 2004.10.1158/0008-5472.CAN-04-1600Search in Google Scholar

Brenner GJ, Felten SY, Felten DL, Moynihan JA. Sympathetic nervous system modulation of tumor metastases and host defense mechanisms. J Neuroimmunol 37, 191–201, 1992.10.1016/0165-5728(92)90003-4Search in Google Scholar

Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18, 1201–1206, 2012.10.1158/1078-0432.CCR-11-0641Search in Google Scholar

Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 29, 413–420, 2011.10.1200/JCO.2010.28.4455Search in Google Scholar

Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 184, 2449–2457, 2010.10.4049/jimmunol.0903301Search in Google Scholar

Godbout JP, Glaser R. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J Neuroimmune Pharmacol 1, 421–427, 2006.10.1007/s11481-006-9036-0Search in Google Scholar

Grzanna R, Frondoza CG, Otten U. Sympathectomy inhibits growth of a murine plasmacytoma tumor. J Auton Nerv Syst 13, 149–160, 1985.10.1016/0165-1838(85)90031-1Search in Google Scholar

Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D’Agostino R, Jr., Danial N, Datta SR, Kulik G. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest 123, 874–886, 2013.10.1172/JCI63324356180723348742Search in Google Scholar

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714–726, 2013.10.1038/nrc3599Search in Google Scholar

Horvathova L, Padova A, Tillinger A, Osacka J, Bizik J, Mravec B. Sympathectomy reduces tumor weight and affects expression of tumor-related genes in melanoma tissue in the mouse. Stress 19, 528–534, 2016.10.1080/10253890.2016.1213808Search in Google Scholar

Kruszewska B, Felten SY, Moynihan JA. Alterations in cytokine and antibody production following chemical sympathectomy in two strains of mice. J Immunol 155, 4613–4620, 1995.10.4049/jimmunol.155.10.4613Search in Google Scholar

Lackovicova L, Banovska L, Bundzikova J, Janega P, Bizik J, Kiss A, Mravec B. Chemical sympathectomy suppresses fibrosarcoma development and improves survival of tumor-bearing rats. Neoplasma 58, 424–429, 2011.10.4149/neo_2011_05_424Search in Google Scholar

Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS. Autonomic nerve development contributes to prostate cancer progression. Science 341, 1236361, 2013.10.1126/science.1236361Search in Google Scholar

Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. Why stress is BAD for cancer patients. J Clin Invest 123, 558–560, 2013.10.1172/JCI67887Search in Google Scholar

Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res 18, 4895–4902, 2012.10.1158/1078-0432.CCR-12-1087Search in Google Scholar

Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 8, 511–512, 2011.10.1038/nrclinonc.2011.123Search in Google Scholar

Raju B, Haug SR, Ibrahim SO, Heyeraas KJ. Sympathectomy decreases size and invasiveness of tongue cancer in rats. Neuroscience 149, 715–725, 2007.10.1016/j.neuroscience.2007.07.048Search in Google Scholar

Raju B, Hultstrom M, Haug SR, Ibrahim SO, Heyeraas KJ. Sympathectomy suppresses tumor growth and alters geneexpression profiles in rat tongue cancer. Eur J Oral Sci 117, 351–361, 2009.10.1111/j.1600-0722.2009.00646.xSearch in Google Scholar

Romeo HE, Colombo LL, Esquifino AI, Rosenstein RE, Chuluyan HE, Cardinali DP. Slower growth of tumours in sympathetically denervated murine skin. J Auton Nerv Syst 32, 159–164, 1991.10.1016/0165-1838(91)90066-CSearch in Google Scholar

Sephton SE, Dhabhar FS, Keuroghlian AS, Giese-Davis J, McEwen BS, Ionan AC, Spiegel D. Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun 23, 1148–1155, 2009.10.1016/j.bbi.2009.07.00719643176Search in Google Scholar

Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 1, 466–469, 20110.18632/oncotarget.182Search in Google Scholar

Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70, 7042–7052, 2010.10.1158/0008-5472.CAN-10-0522294098020823155Search in Google Scholar

Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12, 369–375, 2006.10.1158/1078-0432.CCR-05-1698314106116428474Search in Google Scholar

Tang J, Li Z, Lu L, Cho CH: beta-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol 23, 533–542, 2013.10.1016/j.semcancer.2013.08.00924012659Search in Google Scholar

Tatsuta M, Iishi H, Baba M, Taniguchi H. Inhibitions by 6-hydroxydopamine and neostigmine singly or together of gastric carcinogenesis induced by N-methyl-N’-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer 51, 767–771, 1992.10.1002/ijc.29105105171612784Search in Google Scholar

Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12, 939–944, 2006.10.1038/nm144716862152Search in Google Scholar

Tilan J, Kitlinska J. Sympathetic Neurotransmitters and Tumor Angiogenesis-Link between Stress and Cancer Progression. J Oncol 2010, 539706, 2010.10.1155/2010/539706287492520508839Search in Google Scholar

Yang EV. Role for catecholamines in tumor progression: possible use for beta-blockers in the treatment of cancer. Cancer Biol Ther 10, 30–32, 2010.10.4161/cbt.10.1.12260304083120505322Search in Google Scholar